scholarly journals Electrophysiological parameters in patients with the «dry» form of age-related macular degeneration treated with polarized polychromatic non-coherent light and dynamic electromyostimulation

2012 ◽  
Vol 93 (6) ◽  
pp. 961-965
Author(s):  
F R Saifullina ◽  
R Z Sharafieva ◽  
V I Pogorel’tsev ◽  
E A Abdulaeva
Keyword(s):  
Macular Degeneration ◽  
Wave Amplitude ◽  
Light Stimulus ◽  
Combined Treatment ◽  
Red Light ◽  
Age Related Macular Degeneration ◽  
Control Group ◽  
Coherent Light ◽  
Age Related ◽  
Wave Latency

Aim. To study the electrophysiological parameters in patients with the «dry» form of age-related macular degeneration before and after combined treatment with polarized polychromatic non-coherent light and dynamic electromyostimulation. Methods. Two groups of patients with the «dry» form of age-related macular degeneration were examined. Patients in the main group (40 patients, 80 eyes) were treated with a combination of polarized polychromatic non-coherent light and dynamic electromyostimulation, patients in the control group (39 patients, 78 eyes) were treated conventionally. Mean age of the patients was 71.3±1.1 years. All patients underwent standard ophthalmic examination. To assess the functional status of the macula, electroretinography was performed using the «Neuro-MVP» device (Ivanovo, Russia). A-wave amplitude and latency on the red light stimulus were examined. Results. A-wave amplitude on macular electroretinogram was 11.9% lower and A-wave latency was 20.8% higher in patients with age-related macular degeneration compared to healthy subjects. A statistically significant improvement of the A-wave amplitude and latency was observed on macular electroretinogram after the combined treatment. A-wave amplitude increased from 13.22±1.36 to 17.17±1.59 µV (p 0.01) after 2 months and up to 17.80±1.60 µV (p 0.05) after 6 months of treatment. A-wave latency decreased from 19.32±0.41 to 18.51±0.36 ms (p 0.01) after 2 months and down to 18.31±0.45 ms (p 0.05) after 6 months of treatment. There was a relevant increase in A-wave amplitude from 13.15±1.09 to 16.3±1.09 µV (p 0.01) and decrease in A-wave latency from 19.23±0.30 to 18.64±0.30 ms (p 0.05) in patients of the control group 2 months after the end of treatment. Conclusion. There were relevant increase in A-wave amplitude and decrease in A-wave latency observed on macular electroretinography after treatment. The proposed treatment method does not cause any complications and can be used as a treatment option in patients with allergic reactions to standard drugs.

scholarly journals Blood antioxidant capacity change in patients with the «dry» form of age-related macular degeneration treated with polarized polychromatic non-coherent light and dynamic electromyostimulation

2012 ◽  
Vol 93 (6) ◽  
pp. 994-996
Author(s):  
F R Saifullina ◽  
R Z Sharafieva ◽  
V I Pogorel’tsev ◽  
F M Fayzrahmanova ◽  
E A Abdulaeva
Keyword(s):  
Visual Acuity ◽  
Antioxidant Capacity ◽  
Macular Degeneration ◽  
Combined Treatment ◽  
Mean Value ◽  
Main Group ◽  
Age Related Macular Degeneration ◽  
Control Group ◽  
Coherent Light ◽  
Age Related

Aim. To assess the antioxidant capacity in patients with the «dry» form of age-related macular degeneration before and after combined treatment with polarized polychromatic non-coherent light and dynamic electromyostimulation. Methods. Two groups of patients with the «dry» form of age-related macular degeneration were examined. 40 patients (80 eyes) from the main group were treated using combined treatment and 39 patients (78 eyes) in the group of control who were treated conventionally. The integral blood antioxidant capacity was measured by galvanometry. Results. Blood antioxidant capacity in healthy subjects is 26.0 kC/l. In patients of the main group blood antioxidant capacity before the treatment was equal to 22.81±0.27 kC/l, compared to 22.17±0.20 kC/l in control group (total mean value 22.49±0.27 kC/l). There was a relevant elevation of the blood antioxidant capacity at the late stages after the treatment - up to 12 months, compared to only 2 months in the control group. Visual acuity in patients of the main group before the treatment was 0.87±0.02, after the treatment was finished - 0.96±0,01 (p 0.001), 2 months after the treatment - 0.95±0.01 (p 0.001), 6 months after the treatment - 0.96±0.01 (p 0.001), 12 months after the treatment - 0.95±0.01 (p 0.001). Visual acuity in patients of the control group before the treatment was 0.91±0.02, after the treatment was finished - 0.95±0.02 (p 0.05), 2 months after the treatment - 0.94±0.02 (p 0.05), 6 months after the treatment - 0.92±0.02 (p 0.05). 12 months after the treatment the visual acuity deteriorated compared to the treatment start and was measured as 0.89±0.02. Conclusion. There is a decrease of blood antioxidant capacity (22.49±0.27 kC/l) in patients with the «dry» form of age-related macular degeneration; a relevant increase of blood antioxidant capacity and visual acuity can be observed up to 12 months after the treatment with polarized polychromatic non-coherent light and dynamic electromyostimulation.

scholarly journals Change of electrical impedance measurements on brain in patients with the «dry» form of age-related macular degeneration treated with polarized polychromatic non-coherent light and dynamic electromyostimulation

2012 ◽  
Vol 93 (6) ◽  
pp. 981-984
Author(s):  
F R Saifullina ◽  
R Z Sharafieva ◽  
V I Pogorel’tsev ◽  
E A Abdulaeva
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
Cerebral Circulation ◽  
Stress Ratio ◽  
Combined Treatment ◽  
Age Related Macular Degeneration ◽  
Peak Amplitude ◽  
Coherent Light ◽  
Age Related ◽  
Posterior Cerebral Circulation

Aim. To study the change of electrical impedance measurements in brain in patients with the «dry» form of age-related macular degeneration before and after combined treatment with polarized polychromatic non-coherent light and dynamic electromyostimulation. Methods. Two groups of patients with the «dry» form of age-related macular degeneration were examined. 40 patients (80 eyes) from the main group were treated using combined treatment and 39 patients (78 eyes) in the group of control who were treated conventionally. Results. Before the treatment, decreased blood flow in the internal carotid artery was found in 77.2%, and in the vertebral arteries in 82.2% of patients. Peak amplitude and the stress ratio index at rheoencephalography in the anterior cerebral circulation were 0.83±0.04 Ω and 27.46±0.40%, in the posterior cerebral circulation - 0.70±0.04 Ω and 23.78±0.35%. Peak amplitude values and the stress ratio index have improved significantly right after treatment and after 6 months in the main group compared to the control group. Mean visual acuity in the main group before treatment was 0.87±0.02, right after the treatment - 0.96±0.01 (p 0.001), 2 months after the treatment - 0.95±0.01 (p 0.001), 6 months after the treatment - 0.96±0.01 (p 0.001), 12 months after the treatment - 0.95±0.01 (p 0.001). In the control group mean visual acuity was 0.91±0.02 before the treatment, 0.95±0.02 (p 0.05) - right after the treatment. 2 months after the treatment - 0.94±0.02 (p 0.05), 6 months after the treatment - 0.92±0.02 (p 0.05). 12 months after the treatment mean visual acuity decreased and equaled 0.89±0.02. Decrease of anterior cerebral circulation was found in 77.2% of patients with the «dry» form of age-related macular degeneration, mean peak amplitude value was 0.83±0.04 Ω and the stress ratio index was 27.46±0.40%, decrease of posterior cerebral circulation was found in 82.2% of patients, mean peak amplitude value and the stress ratio index were 0.70±0.04 Ω and 23.78±0.35%. Conclusion. In patients with the «dry» form of age-related macular degeneration posterior cerebral circulation has improved significantly and visual acuity has improved 6 months after combined treatment with polarized polychromatic non-coherent light and dynamic electromyostimulation.

scholarly journals Association of age-related macular degeneration on fracture risks among osteoporosis population: a nationwide population-based cohort study

BMJ Open ◽  
2020 ◽  
Vol 10 (9) ◽  
pp. e037028
Author(s):  
Chi Chin Sun ◽  
Ting-Shuo Huang ◽  
Tsai-Sheng Fu ◽  
Chia-Yi Lee ◽  
Bing-Yu Chen ◽  
...  
Keyword(s):  
Visual Impairment ◽  
Macular Degeneration ◽  
Hip Fractures ◽  
Multivariable Analysis ◽  
Age Related Macular Degeneration ◽  
Control Group ◽  
Research Database ◽  
Risk Of Death ◽  
Age Related ◽  
Ulnar Fracture

ObjectivesVisual impairment is an important risk factor for fracture in the elderly population. Age-related macular degeneration (AMD) is the leading cause of irreversible visual impairment in elderly people. This study was conducted to explore the relationship between AMD and incident fractures in patients with osteoporosis (OS).DesignRetrospective analysis of Taiwan’s National Health Insurance Research Database (NHIRD).SettingA multicenter study conducted in Taiwan.Participants and controlsThe current study used the NHIRD in Taiwan between 1996 and 2011. A total of 13 584 and 54 336 patients with OS were enrolled in the AMD group and the non-AMD group, respectively.InterventionPatients with OS were included from the Taiwan’s NHIRD after exclusion, and each patient with AMD was matched for age, sex and comorbidities to four patients with non-AMD OS, who served as the control group. A Cox proportional hazard model was used for the multivariable analysis.Primary outcome measuresTransitions for OS to spine fracture, OS to hip fracture, OS to humero-radio-ulnar fracture and OS to death.ResultsThe risks of spine and hip fractures were significantly higher in the AMD group (HR=1.09, 95% CI=1.04 to 1.15, p<0.001; HR=1.18; 95% CI=1.08 to 1.30, p=0.001, respectively) than in the non-AMD group. The incidence of humero-radio-ulnar fracture between AMD and non-AMD individuals was similar (HR=0.98; 95% CI=0.90 to 1.06; p=0.599). However, the risk of death was higher in patients with OS with older age, male sex and all types of comorbidity (p<0.05), except for hyperthyroidism (p=0.200).ConclusionPatients with OS with AMD had a greater risk of spine and hip fractures than did patients without AMD.

scholarly journals Simultaneous Dexamethasone Intravitreal Implant and Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration Resistant to Anti-VEGF Monotherapy

2017 ◽  
Vol 1 (1) ◽  
pp. 65-74 ◽  
Author(s):  
Bozho Todorich ◽  
Aristomenis Thanos ◽  
Yoshihiro Yonekawa ◽  
Gerta Mane ◽  
Madeleine Hasbrook ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Combined Treatment ◽  
Case Series ◽  
Dual Therapy ◽  
Age Related Macular Degeneration ◽  
Treatment Resistant ◽  
Dexamethasone Intravitreal Implant ◽  
Anti Vegf ◽  
Age Related ◽  
Intravitreal Implant

Purpose: To evaluate the efficacy of a dexamethasone intravitreal implant in combination with intravitreal anti-vascular endothelial growth factor (VEGF) agents for treatment-resistant neovascular age-related macular degeneration (nvAMD). Methods: This study was designed as a single-center, retrospective interventional case series. Consecutive patients with treatment-resistant nvAMD underwent simultaneous combined injection of anti-VEGF agent and dexamethasone intravitreal implant. Eighteen patients with mean age of 81.5 years were included. Patients received an average of 26.3 anti-VEGF injections before dual therapy, with a mean follow-up of 8.2 months after dual therapy. Results: Dual therapy produced a significant mean decrease in central foveal thickness (126.3 μm), compared to a mean increase in 29.9 μm when treated with anti-VEGF monotherapy ( P = .0017). Patients also had a mean decrease in macular cube volume of −0.85 mm3 with dual therapy compared to anti-VEGF monotherapy ( P = .0014). There was a moderate correlation between the number of prior anti-VEGF injections and the magnitude of anatomic response, suggesting that shorter disease duration may positively influence response to combined treatment. Although there was a slight trend toward improved mean visual acuity after dual therapy, these differences did not reach statistical significance. Nevertheless, with combination treatment, 33% of patients gained 1 or more lines of vision. Dual therapy resulted in a significantly lower number of required anti-VEGF injections (4.25 vs 5.33) and an increase in the anti-VEGF injection-free interval to 1.41 months from 1.12 months during the 6 months following dual therapy compared to the same interval before dual therapy. Dual therapy was well tolerated; 2 eyes developed mild intraocular pressure elevation effectively managed with topical therapy and 1 patient developed worsening cataract. Conclusions: Combined treatment of anti-VEGF with dexamethasone intravitreal implant is a viable alternative for treatment-resistant nvAMD and may reduce treatment burden. Earlier treatment with dual therapy may be beneficial to maximize anatomic and visual outcomes in these patients.

scholarly journals Long-Term Outcomes of Rheohaemapheresis in the Treatment of Dry Form of Age-Related Macular Degeneration

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Jan Studnička ◽  
Eva Rencová ◽  
Milan Bláha ◽  
Pavel Rozsíval ◽  
Miriam Lánská ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Treated Patient ◽  
Pigment Epithelium ◽  
Age Related Macular Degeneration ◽  
Rheological Parameters ◽  
Control Group ◽  
Long Term Effects ◽  
Age Related

Purpose. Determining long-term effects of rheohaemapheresis on the dry form of age-related macular degeneration.Methods. This study evaluates 19 patients, average age of 67.6 years, treated with rheohaemapheresis and 18 patients, average age of 72.8 years, comprising the control group. Minimum follow up period was 3.5 years. Each treated patient received a series of 8 sessions of rheohaemapheresis of 1.5 plasma volumes within 10 weeks. We measured the drusenoid pigment epithelium detachment (DPED), best-corrected visual acuity (BCVA), electroretinography (ERG), and rheological parameters.Results. In the treatment group, the baseline BCVA was 0.74 (0.36–1.0) 95% CI and BCVA after 3.5 years was 0.79 (0.41–1.0) 95% CI (P=0.726). In the control group, the baseline BCVA was 0.71 (0.15–1.0) 95% CI and BCVA after 3.5 years decreased to 0.7 (0.32–0.87) 95% CI (P=0.031). Baseline DPED was 6.78 ± 3.79 mm2; after 3.5 years, it decreased to 4.13 ± 3.84 mm2(P<0.001). In the control group, the baseline DPED was 4.09 ± 3.48 mm2; after 3.5 years, it increased to 6.69 ± 4.2 mm2(P=0.001). We noted increasing levels of positive wave peaking at 50 milliseconds (P50) after treatment (P=0.022) and a stable amplitude of photopic responses of treated patients.Conclusion. Over the long term, rheohaemapheresis reduced the DPED, improved the function of photoreceptors, and prevented the decline of BCVA.

scholarly journals Preservation of the Photoreceptor Inner/Outer Segment Junction in Dry Age-Related Macular Degeneration Treated by Rheohemapheresis

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Eva Rencová ◽  
Milan Bláha ◽  
Jan Studnička ◽  
Vladimír Bláha ◽  
Miriam Lánská ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Macular Degeneration ◽  
Pigment Epithelium ◽  
Retinal Pigment ◽  
Treated Group ◽  
Plasma Viscosity ◽  
Age Related Macular Degeneration ◽  
Control Group ◽  
Macular Function ◽  
Age Related

Aim. To evaluate the long-term effect of rheohemapheresis (RHF) treatment of age-related macular degeneration (AMD) on photoreceptor IS/OS junction status.Methods. In our study, we followed 24 patients with dry AMD and drusenoid retinal pigment epithelium detachment (DPED) for a period of more than 2.5 years. Twelve patients (22 eyes) were treated by RHF and 12 controls (18 eyes) were randomized. The treated group underwent 8 RHF standardized procedures. We evaluated best-corrected visual acuity, IS/OS junction status (SD OCT), and macular function (multifocal electroretinography) at baseline and at 2.5-year follow-up.Results. RHF caused a decrease of whole-blood viscosity/plasma viscosity at about 15/12%. BCVA of treated patients increased insignificantlyP=0.187from median 74.0 letters (56.2 to 81.3 letters) to median 79.0 letters (57.3 to 83.4 letters), but it decreased significantly from 74.0 letters (25.2 to 82.6 letters) to 72.5 letters (23.4 to 83.1 letters) in the control groupP=0.041. The mfERG responses in the region of eccentricity between 1.8° and 7° were significantly higher in treated patientsP=0.04.Conclusions. RHF contributed to sparing of photoreceptor IS/OS junction integrity in the fovea, which is assumed to be a predictive factor for preservation of visual acuity.

scholarly journals Association between relative telomere length and a genetic variant of SIRT1 gene and age-related macular degeneration

2021 ◽  
Vol 21 (3) ◽  
pp. 143-146
Author(s):  
L.K. Moshetova ◽  
◽  
O.P. Dmitrenko ◽  
O.I. Abramova ◽  
N.S. Karpova ◽  
...  
Keyword(s):  
Macular Degeneration ◽  
Telomere Length ◽  
Genetic Variant ◽  
Age Related Macular Degeneration ◽  
Control Group ◽  
Study Group ◽  
Relative Telomere Length ◽  
Age Related ◽  
Buccal Epithelial Cells ◽  
Sirt1 Gene

One of the most important factors predisposing to the development of age-related macular degeneration (AMD) is aging. Telomeres are important for aging by maintaining genome stability. Aim: to identify the association between relative telomere length of buccal epithelial cells and SIRT1 rs12778366 genetic variation and late AMD. Patients and Methods: 100 patients (200 eyes) were enrolled, i.e., 50 patients with AMD (AREDS category 4) and 50 patients without AMD. Genomic DNA isolated from buccal epithelial cells by phenol-chloroform extraction was used. Genotyping of SIRT1 rs12778366 polymorphic locus was performed by TaqMan® real-time PCR. Telomere length was measured by real-time PCR as described earlier [Cawthon, 2002] using specific primers. Relative telomere length was assessed by the relative telomere to single-copy gene (T/S) ratio. Results: the rate of allele C was 25% in the study group and 14% in the control group (p=0.049). The rate of heterozygotic TC genotype was twice higher in the study group compared to the control group (p=0.045). In heterozygotic carriers of the allele C of the SIRT1 rs12778366 gene, the risk of AMD is 2.048- and 2.425-times higher in сodominant and dominant inheritance pattern, respectively. In patients with late AMD, there are more short telomeres (64% vs. 48% in the control group, р=0.0002). Conclusions: further studies of a polymorphic SIRT1 gene locus in the association with telomere length in a larger sample are required. In the future, these molecular markers can be applied to predict the individual course of AMD and to implement preventive measures. Keywords: age-related macular degeneration, relative telomere length, rs12778366, SIRT1 gene, age-related diseases, buccal epithelium, genetic testing. For citation: Moshetova L.K., Dmitrenko O.P., Abramova O.I. et al. Association between relative telomere length and a genetic variant of SIRT gene and age-related macular degeneration. Russian Journal of Clinical Ophthalmology. 2021;21(3):143–146 (in Russ.). DOI: 10.32364/2311- 7729-2021-21-3-143-146.

Ganglion Cell Layer Thickness Change in Neovascular Age-Related Macular Degeneration Treated With Anti-VEGF Injections

2021 ◽  
pp. 247412642110403
Author(s):  
Dimosthenis Mantopoulos ◽  
Hetal Ray ◽  
George Sanchez ◽  
Russell Pokroy ◽  
Daniel B. Roth
Keyword(s):  
Ganglion Cell ◽  
Macular Degeneration ◽  
Ganglion Cell Layer ◽  
Cell Layer ◽  
Treated Group ◽  
Age Related Macular Degeneration ◽  
Control Group ◽  
Fellow Eye ◽  
Anti Vegf ◽  
Age Related

Purpose: This work assesses bilateral ganglion cell layer–inner plexiform layer (GCL-IPL) thickness changes in patients with unilateral neovascular age-related macular degeneration (nAMD) treated with antivascular endothelial growth factor (anti-VEGF). Methods: In this single-center, retrospective, cohort study, the medical records of patients with unilateral nAMD treated with anti-VEGF were reviewed. The treated group included eyes with newly diagnosed nAMD that subsequently underwent treatment with intravitreal anti-VEGF injections. The control group was the fellow eye with dry AMD. Eyes receiving at least 10 intravitreal injections were included. Measurement of GCL-IPL thickness was performed at different time points using spectral domain–optical coherence tomography. Results: A total of 216 eyes of 108 patients met the inclusion criteria. The mean age ± SD was 80.1 ± 10.7 years. Eyes in the treated group underwent a mean ± SD of 20.2 ± 7.2 injections in 21.3 ± 6.8 months. At baseline, average mean ± SD of GCL-IPL thickness was 73.71 ± 8.81 µm and 73.84 ± 8.26 µm in the treated and fellow eye, respectively ( P = .795). After 10 injections the average thickness was 65.41 ± 14.08 µm and 68.77 ± 13.24 µm in the treated and fellow eye, respectively ( P = .007). The absolute decrease in thickness was significantly greater in the treated eye than the fellow eye (mean ± SD, 8.31 ± 11.19 µm vs 5.07 ± 10.83 µm, respectively; P = .002). Conclusions: GCL-IPL thickness decreased significantly in the treated group more than in the control group after 10 anti-VEGF injections. The mechanism and clinical significance of this observation warrants further study.

Serum levels of ARMS2, COL8A1, RAD51B, and VEGF and their correlations in Age-Related Macular Degeneration

2021 ◽  
Vol 18 ◽  
Author(s):  
Priya Battu ◽  
Kaushal Sharma ◽  
Manjari Rain ◽  
Ramandeep Singh ◽  
Akshay Anand
Keyword(s):  
Macular Degeneration ◽  
Serum Levels ◽  
Cross Sectional Study ◽  
Statistical Correlation ◽  
Age Related Macular Degeneration ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Cross Sectional ◽  
Age Related ◽  
Study Results

Background: Many factors including genetic and environmental are responsible for the incidence of age-related macular degeneration (AMD). However, its pathogenesis has not been clearly elucidated yet. Objective: This study aimed to estimate the Age-Related Maculopathy Susceptibility 2 (ARMS2), Collagen type VIII Alpha 1 chain (COL8A1), Rad 51 paralog(RAD51B), and Vascular Endothelial Growth Factor (VEGF) protein levels in serum of AMD and control participants and to further investigate their correlation to understand AMD pathogenesis. Methods: For this cross-sectional study, 31 healthy control and 57 AMD patients were recruited from Advanced Eye Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India. A blood sample was taken and serum was isolated from it. ELISA(enzyme-linked immunosorbent assay)was used for the estimation of proteins in the serum of patients. Results: ARMS2 and COL8A1 levels were significantly elevated in the AMD group than in the control group. The highest levels of ARMS2, COL8A1, and VEGF proteins were recorded for the wet AMD sub-group. The study results endorsed significant positive correlation between these following molecules; ARMS2 and COL8A1 (r=0.933, p<0.0001), ARMS2 and RAD51B (r=0.704, p<0.0001), ARMS2 and VEGF (r=0.925, p<0.0001), COL8A1 and RAD51B (r=0.736, p<0.0001), COL8A1 and VEGF (r=0.879, p<0.0001),and RAD51B and VEGF (r=0.691, p<0.0001). Conclusion: The ARMS2 and COL8A1 levels were significantly higher and RAD51B was significantly lower in the AMD group than controls. Also, a significant statistical correlation was detected between these molecules, indicating that their interaction may be involved in the pathogenesis of AMD.

To Study The Effect Of Mahatriphaladi Ghrita On Drushtipatalgat Vyadhi W. S. R. to Age Related Macular Degeneration

2018 ◽  
Vol 6 (5th) ◽  
Author(s):  
Sonali vilas Khajekar ◽  
Sandeep K. Nimase
Keyword(s):  
Statistical Analysis ◽  
Macular Degeneration ◽  
Age Related Macular Degeneration ◽  
Control Group ◽  
Age Related ◽  
Degenerative Disorder

ARMD is a degenerative disorder change occurred previously was not reversed by either treatment in particular time of span. After statistical analysis, it was concluded that there is no difference between the applied two treatments. Mean was calculated and observed there was slightly more in the control group but was negligible. Results were equally good with the contemporary modern line of treatment, therefore can be prescribed as an alternative medication which will help patients suffering from ARMD.

Sign in / Sign up

Export Citation Format

Share Document